Business
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancerYear-end cash and investments of $14.8
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancerYear-end cash and investments of $14.8 million expected to fund operations through the end of Q1 '25Focusing on clinical operational and regulatory progress for a new technology to treat cancerMultiple clinical opportunities in cancer types having high unmet medical needUpcoming clinical milestonesSHELTON, Conn., March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (\"Intensity\" or \"the Company\") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces full year 2023 financial results and provides a review of 2023 accomplishments and anticipated upcoming developments.\n\n \n \n \n \n \n \n\n \n2023 and Other Recent Highlights\nStudy May Proceed letter received from the U.S. Food and Drug Administration (\"FDA\") for the Company's Phase 3 protocol in soft tissue sarcoma using INT230-6 (the \"INVINCIBLE-3\" study)Completed IT-01 study, a 110-patient Phase 1/2 study using INT230-6 in refractory cancersDosing completed in over 20 different cancers, with favorable safety and strong signals of efficacy shown with immune activationCompleted dosing, database lock and tables, listings and figures for a 91-patient Phase 2 study using INT230-6 in pre-adjuvant breast cancer (the \"INVINCIBLE-2\" study)Presented INVINCIBLE-2 data at the San Antonio Breast Cancer Symposium (\"SABCS\") in an oral podium spotlight discussion sessionINT230-6 induced up to 95% necrosis in tumors following a single injectionFavorable safety profile observedIncrease in CD4 T-cells and NK cells observed within tumorsData presented at Connective Tissue Oncology Society (\"CTOS\") Annual Meeting showing INT230-6 extended survival in refractory soft tissue sarcoma subjects by 15 months compared to a synthetic control group with a 93% disease control rate when used as monotherapyReceived Orphan Drug Designation for the three key ingredients in INT230-6 for the treatment of soft tissue sarcomaPresented two posters at the American Society of Clinical Oncology (\"ASCO\") Annual Meeting reporting anti-cancer immune activation in both breast cancer and sarcoma, w...